

**Joint working executive summary**

<p align="center"><b>Project title</b></p>	<p>Implementation of an optimised lipid management pathway across primary &amp; secondary care (Northumbria Healthcare and Northumberland CCG,)</p>
<p align="center"><b>Partner organisation/s</b></p>	<p>Northumbria Hospitals NHS Foundation Trust &amp; Sanofi.</p> <p><i>This Project has been agreed as part of the Accelerated Access Collaborative (AAC).</i></p> <p><i>The AAC was formed in response to the independently-chaired Accelerated Access Review published in October 2016. The AAC brings industry, government and the NHS together to remove barriers to uptake of innovations, so that NHS patients have faster access to innovations that can transform care.</i></p> <p><i>The AAC supports the rapid uptake of products from 7 high-potential technology areas, selected by leaders in the health and care system, with full evidence-based recommendations from NICE, and have potential to deliver cost-savings in year.</i></p> <p><i>PCSK9 inhibitors for the management of hypercholesterolemia were selected as one of the seven NICE recommended rapid uptake products (RUP) to increase patient access and remove barriers across the health innovation landscape.</i></p> <p><i>Funding announced by government in July 2017 is available through the new Accelerated Access Collaborative Pathway Transformation Fund (PTF) to help NHS organisations integrate the rapid uptake products into everyday practices. Delivered with the support of the Academic Health Science Networks (AHSNs) the PTF seeks to improve equality of access to these products.</i></p> <p><i>The PTF, in relation to PCSK9 inhibitors, combines funding from NHS England, Amgen and Sanofi for selected projects to meet the AAC objectives and increase PCSK9i uptake by addressing barriers such as:</i></p> <ul style="list-style-type: none"> <li><i>• Lack of patient identification</i></li> <li><i>• Inconsistent Pathways</i></li> <li><i>• Limited awareness</i></li> <li><i>• Restricted prescribing</i></li> <li><i>• Sporadic LDL-C measurement</i></li> <li><i>• Treatment complexity</i></li> </ul> <p><i>19 applications relating to PCSK9 inhibitors from 12 AHSNs were submitted to the AAC for PFT funding (funding from NHS England, Amgen and Sanofi) and 6 were selected, including Northumbria Hospitals NHS Foundation Trust. Please see resources and costs for more detail</i></p> <p><i>NHS England have provided equal PTF to the Academic Health and Science Network North East North Cumbria (AHSN-NENC). AHSN-</i></p>

	<p><i>NENC will distribute this accordingly as agreed by the AAC to the 6 successful sites, one of which being Partner for the Project.</i></p> <p><i>Details of the parallel funding can be found on Amgen's joint working website.</i></p>
<b>Project rationale</b>	<p>This project is a patient identification project, case finding across both Primary &amp; Secondary care.</p> <p>Currently there are specialist Lipid clinics operating on three different sites within the Trust, the project will deliver three aspects to improve and develop the current pathway.</p> <ol style="list-style-type: none"> <li>1. Identification of patients Post ACS.</li> <li>2. Retrospective identification of high-risk patients with atherosclerotic cardiovascular disease (ASCVD) in the community</li> <li>3. Pharmacist led lipid optimisation clinic. Patients identified prospectively in 1. or retrospectively for 2. and in whom Lipid management has not been optimised and may be eligible for medication which can only be prescribed in secondary care.</li> </ol>
<b>Project period</b>	Quarter 2 2020- Quarter 4 2021.
<b>Project objectives</b>	<p>The joint working project is designed to support implementation of NICE CG181, TA393 &amp; TA394.</p> <p>Key outputs from the project may include the following: -</p> <ul style="list-style-type: none"> <li>• Rapid access to a specialist lipid service</li> <li>• Optimisation of treatment and support in lipid management</li> <li>• The project will allow support for GPs to achieve the PRIMARY CARE Network DES.</li> <li>• Demonstrates collaborative working with the NHS to the benefit of patients</li> <li>• The results of the project will be written up and published to enable the learnings from the project to be shared.</li> </ul>
<b>Contact details</b>	<p><i>Sanofi- Fleur Chandler,</i>  <i>410 Thames Valley Park Drive, Reading, Berkshire. RG6 1PT.</i>  <a href="mailto:gb-marketaccess@sanofi.com">gb-marketaccess@sanofi.com</a></p> <p><i>Consultant Chemical Pathologist- Dr Stewart Pattman</i>  <i>Northumbria Healthcare NHS Foundation Trust</i>  <i>Rake Lane, North Shields Tyne &amp; Wear NE29 8NH</i>  <i>Telephone: - 0191 293 2546</i></p>